The incidence of hypermobility syndrome in girls aged 16-18
Abstract
Introduction. Joint hypermobility is a rarely diagnosed abnormality, which may be due to the fact that young people excessive range of motion is considered to be normal, and among adults and olders causes of reported pain is seen in/believed to be other diseases. The aim of this study was to determine the prevalence of generalized joint hipermobility in girls aged 16-18 years. Material and methods. The study included 96 girls aged 16-18 years. To assess hypermobility the Beighton scale and Bulbena scale were used. Measurements of height and weight were also made. The study was complemented by an original survey/ questionnaire. Queries related to the presence of pain and its location, the history of the injury and the subjective assessment of vulnerability to injury. Results. Based on the obtained results, it was found that the incidence of hypermobility among examined girls was 28% in the assessment using Beighton scale and 45% based on the Bulbena scale. The correlation between the two scales was defined as high (r = 0.58). The relationship between BMI factor and the amount of points in Bulbena scale was poor (r = -0.21), and between the BMI and the amount of points in Beighton scale that was found no correlation (r = 0.01). When determining the susceptibility to injury, a recurrence of an injury was reported in 42% girls with hypermobility examined using Beighton scale and in 29% of girls with hypermobility examined using Bulbena scale. Conclusions. The incidence of…
Read the paper
Related studies
- PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0
- Randomized controlled trial for time-restricted eating in healthy volunteers without obesity
- Intracorporeal or Extracorporeal Ileocolic Anastomosis After Laparoscopic Right Colectomy: A Double-blinded Randomized Controlled Trial
- Updates to Male Infertility: AUA/ASRM Guideline (2024)
- Effects of trauma‐informed approaches in schools: A systematic review
- Targeted T cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.